External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.
<h4>Background</h4>With growing evidence on the role of inflammation in cancer biology, the presence of a systemic inflammatory response has been postulated as having prognostic significance in a wide range of cancer types. The derived neutrophil to lymphocyte ratio (dNLR), which represe...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b42d4c9e9fa14ea0b38e747247d583ef |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b42d4c9e9fa14ea0b38e747247d583ef |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b42d4c9e9fa14ea0b38e747247d583ef2021-11-18T08:48:35ZExternal validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.1932-620310.1371/journal.pone.0078225https://doaj.org/article/b42d4c9e9fa14ea0b38e747247d583ef2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24223776/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>With growing evidence on the role of inflammation in cancer biology, the presence of a systemic inflammatory response has been postulated as having prognostic significance in a wide range of cancer types. The derived neutrophil to lymphocyte ratio (dNLR), which represents an easily determinable potential prognostic marker in daily practise and clinical trials, has never been externally validated in pancreatic cancer (PC) patients.<h4>Methods</h4>Data from 474 consecutive PC patients, treated between 2004 and 2012 at a single centre, were evaluated retrospectively. Cancer-specific survival (CSS) was assessed using the Kaplan-Meier method. To evaluate the prognostic relevance of dNLR, univariate and multivariate Cox regression models were applied.<h4>Results</h4>We calculated by ROC analysis a cut-off value of 2.3 for the dNLR to be ideal to discriminate between patients' survival in the whole cohort. Kaplan-Meier curve reveals a dNLR≥2.3 as a factor for decreased CSS in PC patients (p<0.001, log-rank test). An independent significant association between high dNLR≥2.3 and poor clinical outcome in multivariate analysis (HR = 1.24, CI95% = 1.01-1.51, p = 0.041) was identified.<h4>Conclusion</h4>In the present study we confirmed elevated pre-treatment dNLR as an independent prognostic factor for clinical outcome in PC patients. Our data encourage independent replication in other series and settings of this easily available parameter as well as stratified analysis according to tumor resectability.Joanna SzkanderaMichael StotzFlorian EisnerGudrun AbsengerTatjana StojakovicHellmut SamoniggPeter KornpratRenate Schaberl-MoserWael AlzoughbiAnna Lena RessFriederike Sophia SeggewiesArmin GergerGerald HoeflerMartin PichlerPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e78225 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Joanna Szkandera Michael Stotz Florian Eisner Gudrun Absenger Tatjana Stojakovic Hellmut Samonigg Peter Kornprat Renate Schaberl-Moser Wael Alzoughbi Anna Lena Ress Friederike Sophia Seggewies Armin Gerger Gerald Hoefler Martin Pichler External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| description |
<h4>Background</h4>With growing evidence on the role of inflammation in cancer biology, the presence of a systemic inflammatory response has been postulated as having prognostic significance in a wide range of cancer types. The derived neutrophil to lymphocyte ratio (dNLR), which represents an easily determinable potential prognostic marker in daily practise and clinical trials, has never been externally validated in pancreatic cancer (PC) patients.<h4>Methods</h4>Data from 474 consecutive PC patients, treated between 2004 and 2012 at a single centre, were evaluated retrospectively. Cancer-specific survival (CSS) was assessed using the Kaplan-Meier method. To evaluate the prognostic relevance of dNLR, univariate and multivariate Cox regression models were applied.<h4>Results</h4>We calculated by ROC analysis a cut-off value of 2.3 for the dNLR to be ideal to discriminate between patients' survival in the whole cohort. Kaplan-Meier curve reveals a dNLR≥2.3 as a factor for decreased CSS in PC patients (p<0.001, log-rank test). An independent significant association between high dNLR≥2.3 and poor clinical outcome in multivariate analysis (HR = 1.24, CI95% = 1.01-1.51, p = 0.041) was identified.<h4>Conclusion</h4>In the present study we confirmed elevated pre-treatment dNLR as an independent prognostic factor for clinical outcome in PC patients. Our data encourage independent replication in other series and settings of this easily available parameter as well as stratified analysis according to tumor resectability. |
| format |
article |
| author |
Joanna Szkandera Michael Stotz Florian Eisner Gudrun Absenger Tatjana Stojakovic Hellmut Samonigg Peter Kornprat Renate Schaberl-Moser Wael Alzoughbi Anna Lena Ress Friederike Sophia Seggewies Armin Gerger Gerald Hoefler Martin Pichler |
| author_facet |
Joanna Szkandera Michael Stotz Florian Eisner Gudrun Absenger Tatjana Stojakovic Hellmut Samonigg Peter Kornprat Renate Schaberl-Moser Wael Alzoughbi Anna Lena Ress Friederike Sophia Seggewies Armin Gerger Gerald Hoefler Martin Pichler |
| author_sort |
Joanna Szkandera |
| title |
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| title_short |
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| title_full |
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| title_fullStr |
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| title_full_unstemmed |
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| title_sort |
external validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/b42d4c9e9fa14ea0b38e747247d583ef |
| work_keys_str_mv |
AT joannaszkandera externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT michaelstotz externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT florianeisner externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT gudrunabsenger externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT tatjanastojakovic externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT hellmutsamonigg externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT peterkornprat externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT renateschaberlmoser externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT waelalzoughbi externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT annalenaress externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT friederikesophiaseggewies externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT armingerger externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT geraldhoefler externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients AT martinpichler externalvalidationofthederivedneutrophiltolymphocyteratioasaprognosticmarkeronalargecohortofpancreaticcancerpatients |
| _version_ |
1718421282990587904 |